{"id":"placebo-of-gasmotin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo of Gasmotin, this product contains no active ingredient and produces no direct pharmacological effect. It is used as a control in clinical trials to assess the efficacy of the active Gasmotin formulation through comparison of outcomes between treatment and placebo groups.","oneSentence":"This is a placebo formulation with no active pharmacological mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:07.472Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent)"}]},"trialDetails":[{"nctId":"NCT07096921","phase":"NA","title":"The Effect of Two Prokinetics in Patients With Functional Dyspepsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eunpyeong St. Mary's Hospital","startDate":"2025-07-08","conditions":"Functional Dyspepsia","enrollment":92},{"nctId":"NCT03024086","phase":"PHASE3","title":"Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2016-12-12","conditions":"Functional Dyspepsia","enrollment":124},{"nctId":"NCT03184402","phase":"PHASE3","title":"Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-04-24","conditions":"Functional Dyspepsia","enrollment":124},{"nctId":"NCT02180334","phase":"PHASE4","title":"The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":12},{"nctId":"NCT03225248","phase":"PHASE3","title":"Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia","status":"COMPLETED","sponsor":"Korea United Pharm. Inc.","startDate":"2014-11-05","conditions":"Functional Dyspepsia","enrollment":143},{"nctId":"NCT02984930","phase":"NA","title":"Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2016-12","conditions":"Gastroesophageal Reflux Disease","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Gasmotin","genericName":"Placebo of Gasmotin","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in clinical trials for Gasmotin (active ingredient: mosapride or similar prokinetic agent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}